Posted by Michael Wonder on 19 Oct 2021
Dr. Reddy's Laboratories announces approval for lenalidomide capsules from the U.S. FDA
19 October 2021 - Dr. Reddy’s Laboratories today announced the final approval of its abbreviated new drug application for lenalidomide 2.5 mg & 20 mg capsules and tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths, a therapeutic equivalent generic version of Revlimid (lenalidomide) capsules, from the U.S. FDA.
With this approval, Dr. Reddy’s is eligible for 180 days of generic drug exclusivity for lenalidomide 2.5 mg and 20 mg capsules.
